In recent research, CAR-T cell therapy targeting the CD19 antigen and B-cell maturation antigen (BCMA) has emerged as a promising treatment option for blood cancers such as lymphoma, leukemia, and myeloma, with six CAR-T cell products receiving approval from the US FDA.36–39. This evidence concerns the gene TNFRSF17 and leukemia.